Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:35:25.566Z.
Calculation as of: 2026-10-06T20:35:25.566Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a397cd850420951a0c9724a6b76f21fabdb26d17d869f1b33831b183cdf643d3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$1.81M
PS Ratio
604.35
TTM Avg
1172.40
3Y Avg
1227.41
5Y Avg
895.29
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Autonomix Medical, Inc. (AMIX) | $1.88M | N/A | N/A | N/A | N/A |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | 0.35 | 1.78 | 1.28 | 11.40 |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | 0.24 | 1.85 | 71.30 | 290.28 |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | 604.35 | 1172.40 | 1227.41 | 895.29 |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A | 1.63 | 5.61 | 81.97 |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | 30.26 | 57.06 | 60.41 | 96.69 |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | 0.10 | 0.80 | 1.03 | 1.35 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q3 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-11 |
| Q4 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-27 |
| Q1 FY2027Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
